Regeneron

YTD

ALL

Trade Regeneron 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About REGN

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara.

CEO

Leonard S. Schleifer

CEOLeonard S. Schleifer

Employees

15,410

Employees15,410

Headquarters

Tarrytown, New York

HeadquartersTarrytown, New York

Founded

1988

Founded1988

Employees

15,410

Employees15,410

REGN Key Statistics

Market cap

82.90B

Market cap82.90B

Price-Earnings ratio

20.24

Price-Earnings ratio20.24

Dividend yield

0.45%

Dividend yield0.45%

Average volume

659.22K

Average volume659.22K

High today

$819.09

High today$819.09

Low today

$801.22

Low today$801.22

Open price

$819.09

Open price$819.09

Volume

527.72K

Volume527.72K

52 Week high

$859.34

52 Week high$859.34

52 Week low

$572.75

52 Week low$572.75

Stock Snapshot

The current Regeneron(REGN) stock price is $804.00, with a market capitalization of 82.9B. The stock trades at a price-to-earnings (P/E) ratio of 20.24 and offers a dividend yield of 0.45%.

During the trading session on 2026-10-23, Regeneron(REGN) shares reached a daily high of $819.09 and a low of $801.22. At a current price of $804.00, the stock is +0.3% higher than the low and still -1.8% under the high.

Trading volume for Regeneron(REGN) stock has reached 527.72K, versus its average volume of 659.22K.

Over the past 52 weeks, Regeneron(REGN) stock has traded between a high of $859.34 and a low of $572.75.

REGN News

Investing.com 9h

Regeneron stock may move 4.4% on Oct. 30 earnings report - Investing.com

...

Simply Wall St 19h

Regeneron Pharmaceuticals Pushes Ahead In Weight Loss With Two Distinct Drug Bets

Regeneron Pharmaceuticals (NasdaqGS:REGN) reported progress on two obesity drug candidates, olatorepatide and trevogrumab, in October 2026. Internal data indic...

TipRanks 2d

Regeneron price target raised to $980 from $960 at TD Cowen

TD Cowen raised the firm’s price target on Regeneron (REGN) to $980 from $960 and keeps a Buy rating on the shares. The fim updated its model ahead of Q3 result...

Analyst ratings

65%

of 31 ratings

Buy

64.5%

Hold

29%

Sell

6.5%

More REGN News

The Motley Fool 4d

Forget Eli Lilly and Novo: This Biotech Could Be a Surprising Winner in the Weight Loss Market

The weight-loss market is growing rapidly, and while long-term projections differ on how large it will become, they generally agree that it will maintain its up...

TipRanks 4d

Regeneron price target raised to $865 from $854 at Piper Sandler

Piper Sandler raised the firm’s price target on Regeneron (REGN) to $865 from $854 and keeps an Overweight rating on the shares. Ahead of Q3 2026 earnings for t...

Simply Wall St 5d

How Investors Are Reacting To Regeneron Pharmaceuticals 84 Week Pasatru Results

Regeneron Pharmaceuticals reported new 84 week Phase 3 OPTIMA data for Pasatru in adults with fibrodysplasia ossificans progressiva, showing sustained control o...

People also own

Based on the portfolios of people who own REGN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.